Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A drug for the symptomatic treatment of hyperkinetic movement disorder.

Etymologies

Sorry, no etymologies found.

Examples

  • Product revenue was up 23% to $231 million on higher revenue from Wellbutrin XL, Biovail Pharmaceuticals Canada, tetrabenazine products, the Zovirax line, its generics portfolio and Legacy products.

    Biovail's Net Up 42%

  • Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine.

    The Neuropsychiatric Guide to Modern Everyday Psychiatry

  • Administering neurotransmitter depleting drugs, such a reserpine (an old blood pressure medication) and tetrabenazine (used to treat movement disorders) 6.

    OpEdNews

  • Huntington's disease, tetrabenazine, treats only motor symptoms and does not alter the course of the disease or prevent cognitive decline.

    THE MEDICAL NEWS

  • The only approved therapy for Huntington's disease, tetrabenazine, treats only motor symptoms and does not alter the course of the disease or prevent cognitive decline.

    Newswise: Latest News

  • Biovail will also incur a full-year's worth of (1) interest expense (both cash and non-cash), and (2) amortization of intangible assets associated with the acquisitions of Wellbutrin XL® in May 2009 and the worldwide development and commercialization rights to tetrabenazine in June 2009.

    THE MEDICAL NEWS

  • Product revenues for the fourth quarter of 2009 were $231.6 million, compared with $171.4 million in the fourth quarter of 2008, an increase of 35% that primarily reflects higher revenues from Wellbutrin XL® and the inclusion of revenues from tetrabenazine products and Aplenzin ™.

    THE MEDICAL NEWS

  • Biovail's global tetrabenazine franchise generated revenues of $53.5 million, compared with

    THE MEDICAL NEWS

  • The Company had $350 million in Convertible Notes outstanding, other long-term obligations of $27.8 million representing the balance of the purchase price arising from the acquisition of the worldwide development and commercialization rights to tetrabenazine in June 2009, and no outstanding borrowings under its committed $410-million revolving credit facility, which represents a reduction of $55 million relative to the end of the third quarter of 2009.

    THE MEDICAL NEWS

  • Following the acquisition of the worldwide development and commercialization rights to tetrabenazine in June 2009, Biovail recorded $1.6 million in revenues in the fourth quarter of 2009 from sales of the product in Europe and around the world.

    THE MEDICAL NEWS

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.